

ASPEN PHARMACARE HOLDINGS LIMITED AND ITS SUBSIDIARIES
Incorporated in the Republic of South Africa
Registration number: 1985/002935/06
JSE Share code: APN
ISIN: ZAE00066692
LEI: 635400ZYSN1IRD5QWQ94
("Aspen" or "the Group")

REVIEWED PROVISIONAL GROUP FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2022 AND CASH DIVIDEND DECLARATION

SALIENT FEATURES

- Revenue from continuing operations increased by 2% (+5% in constant exchange rate ("CER")) to R38,6 billion (FY2021: R37,8 billion);
- Normalised EBITDA from continuing operations increased by 11% (+13% in CER) to R11,0 billion (FY2021: R9,9 billion);
- Normalised headline earnings per share from continuing operations increased by 24% (+26% in CER) to 1 627,6 cents (FY2021: 1 309,7 cents);
- Headline earnings per share from total operations increased by 31% (+31% in CER) to 1 461,2 cents (FY2021: 1 119,1 cents);
- Earnings per share from total operations increased by 36% (+36% in CER) to 1 432,3 cents (FY2021: 1 052,9 cents);
- Dividend declared to shareholders increased by 24% to 326 cents per ordinary share (FY2021: 262 cents);
- Aspen signs 10-year agreement with the world's largest vaccine producer, Serum Institute of India.

DECLARATION OF DIVIDEND

Taking into account the earnings and cash flow performance for the year ended 30 June 2022, existing debt service commitments, future proposed investments and funding options, notice is hereby given that the Board has declared an increased gross dividend of 24%, which is paid from income reserves, of 326 cents per ordinary share to shareholders (or 260,8 cents net of a 20% dividend withholding tax, where this maximum rate of tax applies) recorded in the share register of the Company at the close of business on 23 September 2022 (2021: 262 cents per share). Shareholders should seek their own advice on the tax consequences associated with the dividend and are particularly encouraged to ensure their records are up to date with Aspen so that the correct withholding tax is applied to their dividend. The Company income tax number is 9325178714. The issued share capital of the Company is 446 252 332 ordinary shares. The directors are of the opinion that the Company will, subsequent to the payment of the dividend, satisfy the solvency and liquidity requirements in terms of sections 4 and 46 of the Companies Act, 2008. Future distributions will continue to be decided on a year-to-year basis. In compliance with IAS 10 - Events After Balance Sheet Date, the dividend will be accounted for in the financial statements in the year ended 30 June 2023.

Last day to trade cum dividend	Tuesday, 20 September 2022
Shares commence trading ex dividend	Wednesday, 21 September 2022
Record date	Friday, 23 September 2022
Payment date	Monday, 26 September 2022

Share certificates may not be dematerialised or rematerialised between Wednesday, 21 September 2022 and Friday, 23 September 2022.

REGULATORY REQUIREMENTS

The short form announcement is the responsibility of the Board of Directors of Aspen. The information in the short form announcement is a summary of the full announcement that is available on the Group's website at <https://www.aspenpharma.com/investor-information/>. The full announcement can also be accessed online at <https://senspdf.jse.co.za/documents/2022/jse/isse/APN/YEresults.pdf> or obtained from the Group's registered office (Building 8, Healthcare Park, Woodlands Drive, Woodmead, Sandton) for inspection, at no charge, during office hours on any business day, from the Company Secretary, Riaan Verster, rverster@aspenpharma.com, or from the offices of the sponsor, Investec Bank Limited (100 Grayston Drive, Sandown), from 1 September 2022 to 30 September 2022, both days inclusive. Any investment decisions should be made based on the full announcement published on the JSE Stock Exchange

News Services and published on the Group's website www.aspenpharma.com.

The information in this announcement has been extracted from the reviewed provisional Group financial results for the year ended 30 June 2022, but the short form announcement itself has not been reviewed by the Group's auditors.

REVIEW BY INDEPENDENT AUDITOR

These reviewed provisional Group financial results for the year ended 30 June 2022 have been reviewed by independent external auditors, Ernst & Young Inc. and their unmodified review report is available for inspection at the Group's registered office. The review was performed in accordance with ISRE 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity'. Any reference to future financial performance included in this announcement has not been reviewed or reported on by the Group's external auditors. The auditor's report does not necessarily report on all of the information contained in this announcement/financial results. Shareholders are therefore advised that in order to obtain a full understanding of the nature of the auditor's engagement, they should obtain a copy of the auditor's report, together with the accompanying financial information from the Group's registered office. The Group Chief Financial Officer, Sean Capazorio (CA) SA, supervised the preparation of the reviewed provisional Group financial results for the year ended 30 June 2022.

By order of the Board

KD Dlamini
Chairman

SB Saad
Group Chief Executive

SM Capazorio
Group Chief Financial Officer

Durban
31 August 2022

Sponsor
Investec Bank Limited